|
Promter Hypermethylation and cervical cancer survival |
|||||
| Alive |
Dead |
Hazard Ratio§ |
95%CI |
||
|
|
|||||
| Total loci |
0 |
9 |
2 |
1.00 |
– |
| 1 |
6 |
9 |
0.75 |
0.14–4.00 |
|
| 2 |
13 |
19 |
1.04 |
0.20–5.50 |
|
| ≥3 |
11 |
13 |
1.07 |
0.19–5.92 |
|
| CDH1 |
+ |
18 |
27 |
0.69 |
0.29–1.63 |
| - |
21 |
16 |
1.00 |
– |
|
| DAPK |
+ |
19 |
18 |
0.53 |
0.23–1.19 |
| - |
20 |
25 |
1.00 |
– |
|
| RARB |
+ |
8 |
16 |
1.66 |
0.80–3.46 |
| - |
31 |
27 |
1.00 |
– |
|
| HIC1 |
+ |
7 |
8 |
1.67 |
0.69–4.04 |
| - |
32 |
35 |
1.00 |
– |
|
| FHIT |
+ |
3 |
6 |
1.18 |
0.38–3.66 |
| - |
36 |
37 |
1.00 |
– |
|
| RASSF1A |
+ |
5 |
1 |
2.02 |
0.16–25.08 |
| - |
34 |
42 |
1.00 |
– |
|
| APC |
+ |
4 |
5 |
0.70 |
0.21–2.41 |
| - |
35 |
38 |
1.00 |
– |
|
| CDKN2A |
+ |
2 |
5 |
1.64 |
0.51–5.26 |
| - |
37 |
38 |
1.00 |
– |
|
| MGMT |
+ |
0 |
4 |
2.30 |
0.46–11.45 |
| - |
39 |
39 |
1.00 |
– |
|
| BRCA1 |
+ |
0 |
5 |
3.05 |
0.72–12.93 |
| - |
39 |
38 |
1.00 |
– |
|
|
Adjusted for age (continuous), treatment (3 groups), tumor size (binary), stage (3 groups) and HPV type (4 groups) | |||||
Narayan et al. Molecular Cancer 2003 2:24 doi:10.1186/1476-4598-2-24 |
|||||